Improving Access to Clinical Trials Act of 2009

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;

Client expense: $61,799 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)

Marfan Syndrome Research and Education Programs at NIH and CDC S. 1674 & H.R. 2866: "Improving Access to Clinical Trials Act"

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 2366, The Cancer Coverage Parity Act S1674/HR2866- Improving Access to Clinical Trials Cancer specific issues related to the forthcoming proposed rule on the essential health benefits package

Client expense: $58,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HRes 1433 Resolution Designating September, 2010, Blood Cancer Awareness Month S1674/ HR 2866 Improving Access to Clinical Trials HR 2366 The Cancer Coverage Parity Act

Client expense: $57,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Improving Access to Clinical Trials Act, HR 2866/S 1674

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2366 - Cancer Coverage Parity H Res 1433 - Resolution designating September 2010 as Blood Cancer Awareness Month S 717 - Cancer Alert Act S 1674 / HR 2866 - Improving Access to Clinical Trials Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Marfan Syndrome Research and Education Programs at NIH and CDC S. 1674 & H.R. 2866: "Improving Access to Clinical Trials Act"

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Appropriations for FDA and NIH; HR 2866 the Improving Access to Clinical Trials Act of 2009; GAO Nominations to the Patient-Centered Outcomes Research Institute; SSA compassionate allowance; CMS - Home Infusion; HR 4926 Medical Foods Act;

Client expense: $61,799 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

research funding, rare disease awareness, HR 2866 the Improving Access to Clinical Trials Act, HR 2965 Reauthorizing the Small Business Innovation and Research Act, food and drug safety, access to medical care

Client expense: Not reported · Firm income: Not reported

Marfan Syndrome Research and Education Programs at NIH and CDC S. 1674 & H.R. 2866: "Improving Access to Clinical Trials Act"

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Appropriations Funding for NIH, FDA, AHRQ; support for HR 2866, the Improving Access to Clinical Trials Act; health reform; HR 2965, Reauthorizing the Small Business Innovation and Research Act; Medical Foods Equity Act; Home Infusion Guidance from CMS

Client expense: $44,387 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), Social Security Administration (SSA)

HR 3590 Patient Protection and Affordable Care Act HR 2866/S 1674 Iproving Access to Clinical Trials Act HR 2560.S 1131 Independence at Home Act HR 4272/S 1206 Pediatric Workforce Investment Act

Client expense: $25,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Appropriations funding for NIH, FDA, AHRQ; support for HR 2866 the Improving Access to Clinical Trials Act of 2009; health reform; HR 2965 Reauthorizing the Small Business Innovation and Research Act; Medical Foods Equity Act; home infusion guidance with CMS.

Client expense: $44,567 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), Social Security Administration (SSA)

H.R. 2866 and S. 1674 "Improving Access to Clinical Trials Act of 2009," Appropriations/ NIH & AHRQ, health reform, organ allocations, UNOS - Organ Allocations, Federal funding for research

Client expense: $31,198 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), President of the U.S., SENATE, Social Security Administration (SSA), White House Office

H.R. 2866 and S. 1674 "Improving Access to Clinical Trials Act of 2009," Appropriations/ NIH & AHRQ, health reform, organ allocations, UNOS - Organ Allocations, Federal funding for research

Client expense: $31,198 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), President of the U.S., SENATE, Social Security Administration (SSA), White House Office

H.R. 2866 and S. 1674 "Improving Access to Clinical Trials Act of 2009," Appropriations/ NIH & AHRQ, health reform, organ allocations, UNOS - Organ Allocations, Federal funding for research

Client expense: $31,198 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), President of the U.S., SENATE, Social Security Administration (SSA), White House Office

HR 1030 & S 2803: Tom Lantos Pulmonary Hypertension Research and Education Act HR 1558 & S 623: Pre-existing Condition Patient Protection Act Pulmonary Hypertension Research Prog. at NIH HR 1085 & S 442: Health Insurance Coverage Protection Act Health Ins. Reform Legislation HR 1708 & S 700: Ending the Medicare Disability Waiting Period Act of 2009 H.R. 2866, Improving Access to Clinical Trials Act S. 1674, Improving Access to Clinical Trials Act H.R. 3200, America's Affordable Health Care Choices Act S. 1679, Affordable Health Choices Act H.R. 3962, Affordable Health Care for America Act H.R. 3590, Patient Protection and Affordable Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 1558 & S 623: Pre-existing Condition Patient Protection Act HR 2866, Improving Access to Clinical Trials Act HR 1708 & S 700: Ending the Medicare Disability Waiting Period Act S 1674, Improving Access to Clinical Trials Act HR 1085 & S 442: Health Insurance Coverage Protection Act HR 3200, America's Affordable Health Care Choices Act Marfan Syndrome Research and Education Programs at NIH S 1679, Affordable Health Choices Act HR 3962, Affordable Health Care for America Act HR 3590, Patient Protection and Affordable Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2477: Chemical Facility Security Authorization Act of 2009; provisions regarding chemical facility security. HR 2868: Chemical Facility Anti-Terrorism Act of 2009; provisions regarding chemical security issues and chemical/refinery operations. HR 2866: Improving Access to Clinical Trials Act of 2009; provisions regarding chemical issues.

Client expense: $7,160,000 · Firm income: Not reported

Government targets: Council on Environmental Quality (CEQ), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE

H.R. 3200, the America's Affordable Health Choices Act of 2009, S. 1679 Affordable Health Choices Act of 2009, the Senate's America's Healthy Future Act -- provisions in all three related to hospitals, children's hospitals, children's health, and pediatric workforce issues. S. 621, the Congenital Heart Futures Act, all provisions, S. 1674 and H.R. 2866, Improving Access to Clinical Trials Act of 2009.

Client expense: $111,383 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Improving Access to Clinical Trials Act of 2009, H.R. 2866/S.1674

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2866 and S. 1674 "Improving Access to Clinical Trials Act of 2009," Appropriations/ NIH & AHRQ, health reform, organ allocations

Client expense: $30,187 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), President of the U.S., SENATE, Social Security Administration (SSA), White House Office

HR 1558 & S 623: Pre-existing Condition Patient Protection Act Health Insurance Reform Legislation HR 1708 & S 700: Ending the Medicare Disability Waiting Period Act HR 1085 & S 442: Health Insurance Coverage Protection Act Marfan Syndrome Research and Education Programs at NIH H.R. 2866, Improving Access to Clinical Trials Act S. 1674, Improving Access to Clinical Trials Act H.R. 3200, America's Affordable Health Care Choices Act S. 1679, Affordable Health Choices Act S., America's Health Futures Act of 2009

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

House and Senate FY 10 Labor-HHS-Education Appropriations Bills (Research and Disease Prevention Programs) H.R. 2866, Improving Access to Clinical Trials Act S. 1674, Improving Access to Clinical Trials Act H.R. 3200, America's Affordable Health Care Choices Act S. 1679, Affordable Health Choices Act S., America's Health Futures Act of 2009

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Increased funding for NIH; Support for H.R. 2866, the Improving Access to Clinical Trials Act of 2009; Health Reform; H.R. 2965 Reauthorizing the Small Business Innovation and Research Act

Client expense: $43,826 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA), White House Office